LaMattina
FDA approvals: 1996 versus 2014
January 12, 2015Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing FDA, John LaMattina, LaMattina, NDA, US, appovals, drugs
As highlighted in a number of recent stories, 2014 was a banner year for the biopharmaceutical industry with 41 new …
Drug prices defy gravity – until patent expiry
June 23, 2014Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing John LaMattina, LaMattina, Pfizer, drug, pharma, pricing, research
How drugs are priced is a hot topic these days, and a new Bloomberg article will cause it to heat-up …
John LaMattina: India’s solution to drug costs
May 13, 2013Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing India, LaMattina, R&D
Drug pricing is a major issue in India. The Indian government believes that the prices of lifesaving drugs shouldn’t be …
Ziarco appoints John LaMattina as R&D advisor
March 20, 2013Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing LaMattina, Ziarco
Ex-global head of Pfizer R&D and Pharmafocus regular John LaMattina has been given a strategic advisory role by biotech firm …
Mergers and spending cuts damaging drug research
August 3, 2011Research and Development, Sales and Marketing LaMattina, Pfizer, research productivity
Big pharma’s policy of mergers and swingeing cuts is having a devastating effect on drug research, says a former Pfizer …
Latest content
The evidence bar impacting UK medical cannabis access
November 6, 2026
Addressing the rheumatic disease diagnostic gap in primary care
November 5, 2026
